Clinical Trials
60 trialsASC4START
Novartis
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
SENTRY
Karyopharm Therapeutics Inc
FLUBUTBI
Hackensack Meridian Health
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
APHYPAP
University Hospital, Brest
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
FREEDOM2
Celgene
SURPASS ET
PharmaEssentia
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group
INDEPENDENCE
Celgene
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Siriraj Hospital
FREEDOM
Celgene
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PharmaEssentia Japan K.K.
A Study to Evaluate P1101 in Japanese PV Patients
PharmaEssentia Japan K.K.
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
BMT CTN 0201
Medical College of Wisconsin
OPTIC-2L
Takeda
PAC326
CTI BioPharma
RESPONSE-2
Novartis
CONTI-PV
AOP Orphan Pharmaceuticals AG
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center
Treatment for Chronic Pain in Patients With Advanced Cancer
Canadian Cancer Trials Group
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Incyte Corporation
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center
CICLODECH
Hospital Israelita Albert Einstein
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Alliance for Clinical Trials in Oncology
PEN-PV
AOP Orphan Pharmaceuticals AG
TEAM-ET
AOP Orphan Pharmaceuticals AG
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Fred Hutchinson Cancer Center
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
National Cancer Institute (NCI)
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Children's Oncology Group